Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Out

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Human Reproduction (Oxford, England)|September 2, 1999
What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific businessH J Out, H J Bennink, W N de Laat
Fertility and Sterility|February 11, 1998
Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study GroupH J Coelingh Bennink, B C Fauser, H J Out
Human Reproduction Update|March 1, 1996
Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacyB M Mannaerts, F Rombout, H J Out, et al.
Human Reproduction (Oxford, England)|December 1, 2001
The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatmentsD Sykes, H J Out, S J Palmer, et al.
Clinical and Experimental Rheumatology|May 1, 1992
Detection of the lupus anticoagulant in pregnancyR H Derksen, H J Out, L Blokzijl, et al.
Human Reproduction (Oxford, England)|May 8, 1998
The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilizationP Devroey, H Tournaye, A Van Steirteghem, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 8, 1991
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodiesH J Out, C D Kooijman, H W Bruinse, et al.
Human Reproduction (Oxford, England)|October 1, 1995
A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilizationH J Out, B M Mannaerts, S G Driessen, et al.
Annals of the Rheumatic Diseases|March 1, 1992
Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosusH J Out, M van Vliet, P G de Groot, et al.
Fertility and Sterility|July 1, 1997
Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropinsH J Out, S G Driessen, B M Mannaerts, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Human Reproduction (Oxford, England)|September 2, 1999
What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific businessH J Out, H J Bennink, W N de Laat
Fertility and Sterility|February 11, 1998
Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study GroupH J Coelingh Bennink, B C Fauser, H J Out
Human Reproduction Update|March 1, 1996
Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacyB M Mannaerts, F Rombout, H J Out, et al.
Human Reproduction (Oxford, England)|December 1, 2001
The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatmentsD Sykes, H J Out, S J Palmer, et al.
Clinical and Experimental Rheumatology|May 1, 1992
Detection of the lupus anticoagulant in pregnancyR H Derksen, H J Out, L Blokzijl, et al.
Human Reproduction (Oxford, England)|May 8, 1998
The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilizationP Devroey, H Tournaye, A Van Steirteghem, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 8, 1991
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodiesH J Out, C D Kooijman, H W Bruinse, et al.
Human Reproduction (Oxford, England)|October 1, 1995
A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilizationH J Out, B M Mannaerts, S G Driessen, et al.
Annals of the Rheumatic Diseases|March 1, 1992
Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosusH J Out, M van Vliet, P G de Groot, et al.
Fertility and Sterility|July 1, 1997
Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropinsH J Out, S G Driessen, B M Mannaerts, et al.
Pageof 4